{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:08:04Z","timestamp":1783940884487,"version":"3.55.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Am Psychiatr Nurses Assoc"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>First-line treatment for major depressive disorders (MDDs) is often antidepressants. These medications are commonly trialed and discontinued due to side effects. Pharmacogenetic testing (PGx) allows psychiatric-mental health nurse practitioners to assess patient drug metabolism with the goal of reducing medication trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The purpose of this quality improvement project was to examine the impact of PGx on remission rates and clinical outcomes for MDD compared with the standard of care (SOC) in psychiatry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Outcomes were measured using a problem status system within the site\u2019s electronic health record based on patient self-reports and clinician interpretation. No validated scale was used which represents a methodological limitation to the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The SOC group had higher remission rates of MDD (38%) compared with PGx (9.8%). The PGx group had a higher occurrence of moderate (24.4%) and severe (17.1%) diagnosis of MDD compared with the SOC group (16% and 8%), respectively. The SOC group had a stable problem status (70%) compared with the PGx group (43.9%). The improving status of PGx was 12.2% compared with SOC at 8%, and the worsening problem status of standard care was 10% compared with PGx at 4.9%. Age did not significantly differ by problem status in the PGx group,\n                      <jats:italic toggle=\"yes\">F<\/jats:italic>\n                      <jats:sub>(3, 37)<\/jats:sub>\n                      = 0.592,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .624.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PGx may offer clinical value for patients with severe depression. Results should be interpreted cautiously, and further studies using validated scales and controlled designs are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10783903261431278","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T05:49:29Z","timestamp":1774763369000},"page":"296-302","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetic Testing in Patients With Depression: A Quality Improvement Project"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-8226","authenticated-orcid":false,"given":"Jeremy Tyler","family":"Rockwell","sequence":"first","affiliation":[{"name":"Jeremy Tyler Rockwell, DNP, Troy University, Troy, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4276-6480","authenticated-orcid":false,"given":"Amy Y.","family":"Spurlock","sequence":"additional","affiliation":[{"name":"Amy Y. Spurlock, PhD, RN, Boise State University, Boise, ID, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6326-3164","authenticated-orcid":false,"given":"Kerri L.","family":"Outlaw","sequence":"additional","affiliation":[{"name":"Kerri L. Outlaw, DNP, PMHNP-BC, CNS, RN, The University of Alabama, Tuscaloosa, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"American Academy of Child and Adolescent Psychiatry. (2020). Clinical use of pharmacogenetic tests in prescribing psychotropic medications for children and adolescents. https:\/\/www.aacap.org\/aacap\/Policy_Statements\/2020\/Clinical-Use-Pharmacogenetic-Tests-Prescribing-Psychotropic-Medications-for-Children-Adolescents.aspx"},{"key":"e_1_3_2_3_1","unstructured":"American Psychiatric Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts. https:\/\/www.apa.org\/depression-guideline\/guideline.pdf"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Barlati S. Minelli A. Nibbio G. Bertoni L. Necchini N. Paolini S. Muscarella A. Ubertino U. B. Calzavara-Pinton I. Vita A. Gennarelli M. (2023). The role of pharmacogenetics in the treatment of major depressive disorder: A critical review. Frontiers in Psychiatry 14 Article 1307473. https:\/\/doi.org\/10.3389\/fpsyt.2023.1307473","DOI":"10.3389\/fpsyt.2023.1307473"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Bousman C. A. Bengesser S. A. Aitchison K. J. Amare A. T. Aschauer H. Baune B. T. Asl B. B. Bishop J. R. Burmeister M. Chaumette B. Chen L. S. Cordner Z. A. Deckert J. Degenhardt F. DeLisi L. E. Folkersen L. Kennedy J. L. Klein T. E. McClay J. L. M\u00fcller D. J. (2021). Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry 54(1) 5\u201317. https:\/\/doi.org\/10.1055\/a-1288-1061","DOI":"10.1055\/a-1288-1061"},{"key":"e_1_3_2_6_1","unstructured":"Brody D. J. Hughes J. P. (2025). Depression prevalence in adolescents and adults: United States August 2021\u2013August 2023 (NCHS Data Brief No. 527). U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db527.htm"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Brown L. C. Stanton J. D. Bharthi K. Maruf A. A. M\u00fcller D. J. Bousman C. A. (2022). Pharmacogenomic testing and depressive symptom remission: A systematic review and meta-analysis of prospective controlled clinical trials. Clinical Pharmacology and Therapeutics 112(6) 1303\u20131317. https:\/\/doi.org\/10.1002\/cpt.2748","DOI":"10.1002\/cpt.2748"},{"key":"e_1_3_2_8_1","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics. (2023). 2019 NAMCS national estimates for office-based physicians: Web tables (2019 NAMCS Summary Tables). U.S. Department of Health and Human Services. https:\/\/www.cdc.gov\/nchs\/data\/ahcd\/namcs_summary\/2019-namcs-web-tables-508.pdf"},{"key":"e_1_3_2_9_1","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics. (2024). 2022 NHAMCS emergency department summary tables. U.S. Department of Health and Human Services. https:\/\/www.cdc.gov\/nchs\/data\/nhamcs\/web_tables\/2022-nhamcs-ed-web-tables.pdf"},{"key":"e_1_3_2_10_1","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics. (n.d.). Underlying cause of death 2018-2023 (single race) [Dataset]. CDC WONDER. https:\/\/wonder.cdc.gov\/controller\/saved\/D158\/D420F602"},{"key":"e_1_3_2_11_1","unstructured":"CPIC. (n.d.). What is CPIC? https:\/\/cpicpgx.org"},{"key":"e_1_3_2_12_1","unstructured":"GeneSight. (n.d.). Genesight cost. https:\/\/genesight.com\/cost\/"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Greden J. Parikh S. Rothschild A. Thase M. Dunlop B. DeBattista C. Conway C. Forester B. Mondimore F. Shelton R. Macaluso M. Li J. Brown K. Gilbert A. Burns L. Jablonski M. Dechairo B. (2019). Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the guided trial: A large patient- and rater-blinded randomized controlled study. Journal of Psychiatric Research 111 59\u201367. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.01.003","DOI":"10.1016\/j.jpsychires.2019.01.003"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Greenberg P. Chitnis A. Louie D. Suthoff E. Chen S.-Y. Maitland J. Gagnon-Sanschagrin P. Fournier A.-A. Kessler R. C. (2023). The economic burden of adults with major depressive disorder in the United States (2019). Advances in Therapy 40(10) 4460\u20134479. https:\/\/doi.org\/10.1007\/s12325-023-02622-x","DOI":"10.1007\/s12325-023-02622-x"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Hertz D. L. Bousman C. A. McLeod H. L. Monte A. A. Voora D. Orlando L. A. Crutchley R. D. Brown B. Teeple W. Rogers S. Patel J. N. (2024). Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. American Journal of Health-system Pharmacy 81(16) 672\u2013683. https:\/\/doi.org\/10.1093\/ajhp\/zxae110","DOI":"10.1093\/ajhp\/zxae110"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Hong R. H. Murphy J. K. Michalak E. E. Chakrabarty T. Wang Z. Parikh S. V. Culpepper L. Yatham L. N. Lam R. W. Chen J. (2021). Implementing measurement-based care for depression: Practical solutions for psychiatrists and primary care physicians. Neuropsychiatric Disease and Treatment 17 79\u201390. https:\/\/doi.org\/10.2147\/NDT.S283731","DOI":"10.2147\/NDT.S283731"},{"key":"e_1_3_2_17_1","unstructured":"ISPG (n.d.). About ISPG. https:\/\/ispg.net\/about-us\/"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Jameson A. Fylan B. Bristow G. C. Sagoo G. S. Dalton C. Cardno A. Sohal J. McLean S. L. (2021). What are the barriers and enablers to the implementation of pharmacogenetic testing in mental health care settings? Frontiers in Genetics 12 Article 740216. https:\/\/doi.org\/10.3389\/fgene.2021.740216","DOI":"10.3389\/fgene.2021.740216"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Leitch T. M. Killam S. R. Brown K. E. Katseanes K. C. George K. M. Schwanke C. Loveland J. Elias A. F. Haney K. Krebsbach K. Muzquiz L. I. Trinidad S. B. Woodahl E. L. (2022). Ensuring equity: Pharmacogenetic implementation in rural and tribal communities. Frontiers in Pharmacology 13 Article 953142. https:\/\/doi.org\/10.3389\/fphar.2022.953142","DOI":"10.3389\/fphar.2022.953142"},{"key":"e_1_3_2_20_1","unstructured":"Miller J. (2022 July 7). Psychiatric pharmacogenomics: The evidence base. Psychiatric Times. https:\/\/www.psychiatrictimes.com\/view\/psychiatric-pharmacogenomics-the-evidence-base"},{"key":"e_1_3_2_21_1","unstructured":"Myriad Neuroscience. (2021). Understanding the GeneSight test algorithm. GeneSight. https:\/\/genesight.com\/genetic-insights\/understanding-the-genesight-test-algorithm\/"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Park S. Thigpen J. Lee I. (2020). Coverage of pharmacogenetic tests by private health insurance companies. Journal of the American Pharmacists Association 60(2) 352\u2013356. https:\/\/doi.org\/10.1016\/j.japh.2019.10.003","DOI":"10.1016\/j.japh.2019.10.003"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Patel E. Ramaiah P. Mamaril-Davis J. C. Bauer I. L. Koujah D. Seideman T. Kelbert J. Nosova K. Bina R. W. (2024). Outcome differences between males and females undergoing deep brain stimulation for treatment-resistant depression: Systematic review and individual patient data meta-analysis. Journal of Affective Disorders 351 481\u2013488. https:\/\/doi.org\/10.1016\/j.jad.2024.01.251","DOI":"10.1016\/j.jad.2024.01.251"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Perna G. Alciati A. Dacc\u00f2 S. Grassi M. Caldirola D. (2020). Personalized psychiatry and depression: The role of sociodemographic and clinical variables. Psychiatry Investigation 17(3) 193\u2013206. https:\/\/doi.org\/10.30773\/pi.2019.0289","DOI":"10.30773\/pi.2019.0289"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"Radosavljevic M. Svob Strac D. Jancic J. Samardzic J. (2023). The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. Genes 14(5) 1095. https:\/\/doi.org\/10.3390\/genes14051095","DOI":"10.3390\/genes14051095"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Shaaban S. Ji Y. (2023). Pharmacogenomics and health disparities are we helping? Frontiers in Genetics 14 Article 1099541. https:\/\/doi.org\/10.3389\/fgene.2023.1099541","DOI":"10.3389\/fgene.2023.1099541"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Stevenson J. M. Smith D. M. Tuteja S. Patel J. N.; Pharmacogenomics Global Research Network (PGRN) Publications Committee. (2025). Navigating pharmacogenomic testing in practice: Who to test and when to test. Clinical Pharmacology and Therapeutics 118(3) 561\u2013566. https:\/\/doi.org\/10.1002\/cpt.3704","DOI":"10.1002\/cpt.3704"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Virelli C. R. Mohiuddin A. G. Kennedy J. L. (2021). Barriers to clinical adoption of pharmacogenomic testing in psychiatry: A critical analysis. Translational Psychiatry 11(1) 509. https:\/\/doi.org\/10.1038\/s41398-021-01600-7","DOI":"10.1038\/s41398-021-01600-7"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"Wang X. Wang C. Zhang Y. An Z. (2023). Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: A systematic review and meta-analysis of RCTs. BMC Psychiatry 23(1) Article 334. https:\/\/doi.org\/10.1186\/s12888-023-04756-2","DOI":"10.1186\/s12888-023-04756-2"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Whitmyre E. D. Esposito-Smythers C. L\u00f3pez R.Jr. Goldberg D. G. Liu F. Defayette A. B. (2024). Implementation of measurement-based care in mental health service settings for youth: A systematic review. Clinical Child and Family Psychology Review 27(4) 909\u2013942. https:\/\/doi.org\/10.1007\/s10567-024-00498-z","DOI":"10.1007\/s10567-024-00498-z"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Xavier R. M. (2024). Pharmacogenomic testing and implications for psychiatric medication prescribing. The Nurse Practitioner 49(12) 24\u201333. https:\/\/doi.org\/10.1097\/01.NPR.0000000000000256","DOI":"10.1097\/01.NPR.0000000000000256"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","unstructured":"Yang J. Mishra A. Sinha K. K. (2025). Towards the integration of precision medicine in psychiatric care delivery: Evaluating the impact of clinical guidelines on drug-related adverse events. Journal of Operations Management 71 393\u2013414. https:\/\/doi.org\/10.1002\/joom.1353","DOI":"10.1002\/joom.1353"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"Zare H. Meyerson N. S. Nwankwo C. A. Thorpe R. J.Jr. (2022). How income and income inequality drive depressive symptoms in U.S. adults does sex matter: 2005-2016. International Journal of Environmental Research and Public Health 19(10) 6227. https:\/\/doi.org\/10.3390\/ijerph19106227","DOI":"10.3390\/ijerph19106227"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Zhdanava M. Pilon D. Ghelerter I. Chow W. Joshi K. Lefebvre P. Sheehan J. J. (2021). The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. The Journal of Clinical Psychiatry 82(2) 20m13699. https:\/\/doi.org\/10.4088\/JCP.20m13699","DOI":"10.4088\/JCP.20m13699"}],"container-title":["Journal of the American Psychiatric Nurses Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10783903261431278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10783903261431278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10783903261431278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:52:00Z","timestamp":1783939920000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10783903261431278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/10783903261431278"],"URL":"https:\/\/doi.org\/10.1177\/10783903261431278","relation":{},"ISSN":["1078-3903","1532-5725"],"issn-type":[{"value":"1078-3903","type":"print"},{"value":"1532-5725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}